LAVADOS GERMAIN, PABLO MANUEL

Now showing 1 - 10 of 153

Some of the metrics are blocked by your
consent settings
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
(2015)
LAVADOS GERMAIN, PABLO MANUEL
Scopus© Citations 2410 1
Some of the metrics are blocked by your
consent settings
REGIONAL DIFFERENCES IN EARLY BP MANAGEMENT AFTER ACUTE STROKE IN INTERNATIONAL RANDOMIZED CONTROLLED TRIALS OF 5000 PATIENTS 1 of 1 REGIONAL DIFFERENCES IN EARLY BP MANAGEMENT AFTER ACUTE STROKE IN INTERNATIONAL RANDOMIZED CONTROLLED TRIALS OF 5000 PATIENTS
(2020)
LAVADOS GERMAIN, PABLO MANUEL
;
Song, L.
;
Wang, X.
;
Moullaali, T.
;
Sun, L.
12
Some of the metrics are blocked by your
consent settings
Stroke in Latin America: A systematic review of the incidence, prevalence and case-fatality between 1997-2021
(2022)
LAVADOS GERMAIN, PABLO MANUEL
;
DELFINO, CARLOS
;
Claudia Asenjo-lobos
;
GONZÁLEZ MC CAWLEY, FRANCISCA
;
Amy Riviotta
6
Some of the metrics are blocked by your
consent settings
EFFECT OF AGE ON ARTERIAL RECANALIZATION AND OUTCOME IN THROMBOLYSED ACUTE ISCHEMIC STROKE PATIENTS
(2020)
LAVADOS GERMAIN, PABLO MANUEL
;
BRUNSER RABOVICH, ALEJANDRO MICHEL
;
OLAVARRIA IANISZEWSKY, VERONICA VIVIANA
;
Sharma, A.
;
Tsivgoulis, G.
1
Some of the metrics are blocked by your
consent settings
Incidence of aphasia in patients experiencing an ischemic stroke
(2017)
Francisca González Mc
;
Pablo Lavados G
;
Verónica arría I
8Scopus© Citations 21
Some of the metrics are blocked by your
consent settings
WHY DO CHINESE PATIENTS HAVE BETTER OUTCOME AFTER ICH? INTERACT2 RESULTS
(2021)
LAVADOS GERMAIN, PABLO MANUEL
;
Wang, X
;
Gordon, P.
;
Sandset, E. C.
;
Lindley, R.
1
Some of the metrics are blocked by your
consent settings
Validation of transcranial Doppler in the diagnosis of brain death
(2010-04)
BRUNSER, ALEJANDRO
;
HOPPE WIEGERING, ARNOLD JOHANNES GOTTLIEB
;
Cárcamo, Daniel A.
;
LAVADOS GERMAIN, PABLO MANUEL
;
Roldán, Andrés
1
Some of the metrics are blocked by your
consent settings
Priorities to reduce the burden of stroke in Latin American countries
(2019)
Sheila C Ouriques Martins
;
Claudio Sacks
;
Werner Hacke
;
Michael Brainin
;
Francisco de Assis Figueiredo
Scopus© Citations 107 7
Some of the metrics are blocked by your
consent settings
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
(2017)
Theo Vos
;
Amanuel Alemu Abajobir
;
Kalkidan Hassen Abate
;
Cristiana Abbafati
;
Kaja M Abbas
5Scopus© Citations 6310
Some of the metrics are blocked by your
consent settings
Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial
(2017)
Lily Song
;
Xia Wang
;
Thompson Robinson
;
Richard I Lindley
;
Hisatomi Arima
<jats:sec><jats:title>Background</jats:title><jats:p>The characteristics of patients with acute ischaemic stroke (AIS) and their management vary across regions, which may influence outcomes. We examined for differential patterns of outcome between China and non-China participants of the ENhanced Control of Hypertension And Thrombolysis strokE stuDy (ENCHANTED), which tested different alteplase doses in AIS.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>ENCHANTED was an international, multicentre, open, blinded-endpoint trial of the effects of low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) intravenous alteplase on 90-day disability outcomes and symptomatic intracerebral haemorrhage (sICH) in 3310 patients with AIS.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Participants (n=1419, 48%) in China were younger, and more often male, hypertensive and with prior stroke and coronary artery disease, but less likely to have atrial fibrillation and use antihypertensive, antithrombotic and lipid-lowering agents, compared with non-China patients with AIS. Although China participants had more AIS due to large artery occlusion, were treated later and had differing ancillary management, there was no significant difference in 90-day modified Rankin scale scores 2–6 (55.6% vs 47.8%; OR, adjusted for baseline and management factors 0.87 (95% CI 0.71 to 1.07; p=0.20)) and risk of sICH (Safe Implementation of Thrombolysis in Stroke-Monitoring Study criteria: 1.4% vs 1.8%; p=0.12) compared with non-China participants. There was no heterogeneity in the treatment effects of low-dose versus standard-dose alteplase between China and non-China participants.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Patients with AIS recruited to the ENCHANTED trial in China had similar outcomes in response to thrombolysis treatment despite significantly differing demographic, clinical and management factors to patients with AIS in other regions.</jats:p></jats:sec>
5Scopus© Citations 8

LAVADOS GERMAIN, PABLO MANUEL

Filters

Settings

Sort By

Results per page